A single nucleotide polymorphism in the gene for GPR183 increases its surface expression on blood lymphocytes of patients with inflammatory bowel disease

Swiss IBD Cohort Study Group

doi:10.1111/bph.15395

A single nucleotide polymorphism in the gene for GPR183 increases its surface expression on blood lymphocytes of patients with inflammatory bowel disease

Swiss IBD Cohort Study Group

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Original language	English
Pages (from-to)	3157-3175
Number of pages	19
Journal	British Journal of Pharmacology
Volume	178
Issue number	16
DOIs	https://doi.org/10.1111/bph.15395
State	Published - Aug 2021

Keywords

FACS
GPR183/EBI2
IBD
SNP
UBAC2
psoriasis

Access to Document

10.1111/bph.15395

Cite this

@article{449dcb9acc63423d9b48ea0470b7fbc5,

title = "A single nucleotide polymorphism in the gene for GPR183 increases its surface expression on blood lymphocytes of patients with inflammatory bowel disease",

keywords = "FACS, GPR183/EBI2, IBD, SNP, UBAC2, psoriasis",

author = "{Swiss IBD Cohort Study Group} and Florian Ruiz and Annika Wyss and Rossel, {Jean Beno{\^i}t} and Sulz, {Michael Christian} and Stephan Brand and Anja Moncsek and Mertens, {Joachim C.} and Ren{\'e} Roth and Clottu, {Aur{\'e}lie S.} and Emanuel Burri and Pascal Juillerat and Luc Biedermann and Thomas Greuter and Gerhard Rogler and Caroline Pot and Benjamin Misselwitz and Karim Abdelrahman and Gentiana Ademi and Patrick Aepli and Amman Thomas and Claudia Anderegg and Antonino, {Anca Teodora} and Eva Archanioti and Eviano Arrigoni and Nurullah Aslan and {de Jong}, {Diana Bakker} and Bruno Balsiger and Bruno Balsiger and Barry, {Mamadou Path{\'e}} and Polat Bast{\"u}rk and Peter Bauerfeind and Andrea Becocci and Bengoa, {Jos{\'e} M.} and Luc Biedermann and Janek Binek and Mirjam Blattmann and Stephan Boehm and Tujana Boldanova and Jan Borovicka and Braegger, {Christian P.} and Stephan Brand and Francisco Bravo and Lukas Br{\"u}gger and Simon Brunner and Patrick B{\"u}hr and Sabine Burk and Emanuel Burri and Matthias Butter and Sophie Buyse and Bernhard Sauter",

note = "Funding Information: The authors would like to thank Andreas Sailer, Novartis Institute of Biomedical Research, Basel, Switzerland, for generously providing an GPR183(EBI2)‐antibody and stimulating discussions. This work was supported by grants from the Swiss National Science Foundation (SNF) to B.M. (grant no. 32473B_156525), to C.P. (grant no. PP00P3_157476) and to G.R. (for the Swiss IBD Cohort, grant no. 33CS30_148422), a grant from the Leenaards Foundation to C.P. and a grant from the Hartmann‐M{\"u}ller Foundation to B.M. F.R. holds a MD‐PhD grant from the SNF (#323630‐183987). Funding Information: B.M. has served at an advisory board for Gilead and Novigenix. He has received speaking fees from Vifor, MSD and Takeda and traveling fees from Vifor, Novartis, MSD, Gilead and Takeda. B.M. has received a research grant from MSD unrelated to this work. C.P. has participated in advisory boards for Biogen, Celgene, Merck, Novartis and Roche none related to this work. A.W. is currently an employee of Abbvie. G.R. has consulted to Abbvie, Augurix, BMS, Boehringer, Calypso, Celgene, FALK, Ferring, Fisher, Genentech, Gilead, Janssen, MSD, Novartis, Pfizer, Phadia, Roche, UCB, Takeda, Tillots, Vifor, Vital Solutions and Zeller; GR has received speaker's honoraria from Astra Zeneca, Abbvie, FALK, Janssen, MSD, Pfizer, Phadia, Takeda, Tillots, UCB, Vifor and Zeller; G.R. has received educational grants and research grants from Abbvie, Ardeypharm, Augurix, Calypso, FALK, Flamentera, MSD, Novartis, Pfizer, Roche, Takeda, Tillots, UCB, and Zeller. L.B. reports fees for consulting/advisory board from Abbvie, MSD, Vifor, Falk, Esocap, Calypso, Ferring, Pfizer, Shire, Takeda, Janssen, Ewopharma. M.C.S. has received consultant and/or speaker fees from Abbvie, Ferring, MSD, Janssen, Pfizer, Takeda, and UCB. P.J. has received a research grant from Vifor unrelated to this work. S.B. received fees for consulting and advisory boards and speaker's honoraria from AbbVie, Falk, Janssen‐Cilag AG, MSD, Pfizer, Takeda, UCB Pharma and Vifor Pharma. R.R. has served at an advisory board for Lilly and has received travel fees from AbbVie AG. T.G. has consulting contracts with Sanofi‐Regeneron and Falk Pharma GmbH, received travel grants from Falk Pharma GmbH and Vifor, and an unrestricted research grant from Novartis. E.B. received consultant and/or speaker fees from Abbvie, Janssen, MSD, Norgine, Pfizer, Takeda, and Sandoz. J.C.M. has served at advisory boards and received honoraria from Abbvie, Bayer, BMS, Eisai, Gilead, Incyte, Intercept, Ipsen, MSD, Roche, Sanofi, SigmaTau. J.C.M. received grants from Abbvie, Gilead, and Falk. Funding Information: The authors would like to thank Andreas Sailer, Novartis Institute of Biomedical Research, Basel, Switzerland, for generously providing an GPR183(EBI2)-antibody and stimulating discussions. This work was supported by grants from the Swiss National Science Foundation (SNF) to B.M. (grant no. 32473B_156525), to C.P. (grant no. PP00P3_157476) and to G.R. (for the Swiss IBD Cohort, grant no. 33CS30_148422), a grant from the Leenaards Foundation to C.P. and a grant from the Hartmann-M{\"u}ller Foundation to B.M. F.R. holds a MD-PhD grant from the SNF (#323630-183987).",

year = "2021",

month = aug,

doi = "10.1111/bph.15395",

language = "English",

volume = "178",

pages = "3157--3175",

journal = "British Journal of Pharmacology",

issn = "0007-1188",

publisher = "John Wiley and Sons Inc.",

number = "16",

}

TY - JOUR

T1 - A single nucleotide polymorphism in the gene for GPR183 increases its surface expression on blood lymphocytes of patients with inflammatory bowel disease

AU - Swiss IBD Cohort Study Group

AU - Ruiz, Florian

AU - Wyss, Annika

AU - Rossel, Jean Benoît

AU - Sulz, Michael Christian

AU - Brand, Stephan

AU - Moncsek, Anja

AU - Mertens, Joachim C.

AU - Roth, René

AU - Clottu, Aurélie S.

AU - Burri, Emanuel

AU - Juillerat, Pascal

AU - Biedermann, Luc

AU - Greuter, Thomas

AU - Rogler, Gerhard

AU - Pot, Caroline

AU - Misselwitz, Benjamin

AU - Abdelrahman, Karim

AU - Ademi, Gentiana

AU - Aepli, Patrick

AU - Thomas, Amman

AU - Anderegg, Claudia

AU - Antonino, Anca Teodora

AU - Archanioti, Eva

AU - Arrigoni, Eviano

AU - Aslan, Nurullah

AU - de Jong, Diana Bakker

AU - Balsiger, Bruno

AU - Barry, Mamadou Pathé

AU - Bastürk, Polat

AU - Bauerfeind, Peter

AU - Becocci, Andrea

AU - Bengoa, José M.

AU - Biedermann, Luc

AU - Binek, Janek

AU - Blattmann, Mirjam

AU - Boehm, Stephan

AU - Boldanova, Tujana

AU - Borovicka, Jan

AU - Braegger, Christian P.

AU - Brand, Stephan

AU - Bravo, Francisco

AU - Brügger, Lukas

AU - Brunner, Simon

AU - Bühr, Patrick

AU - Burk, Sabine

AU - Burri, Emanuel

AU - Butter, Matthias

AU - Buyse, Sophie

AU - Sauter, Bernhard

N1 - Funding Information: The authors would like to thank Andreas Sailer, Novartis Institute of Biomedical Research, Basel, Switzerland, for generously providing an GPR183(EBI2)‐antibody and stimulating discussions. This work was supported by grants from the Swiss National Science Foundation (SNF) to B.M. (grant no. 32473B_156525), to C.P. (grant no. PP00P3_157476) and to G.R. (for the Swiss IBD Cohort, grant no. 33CS30_148422), a grant from the Leenaards Foundation to C.P. and a grant from the Hartmann‐Müller Foundation to B.M. F.R. holds a MD‐PhD grant from the SNF (#323630‐183987). Funding Information: B.M. has served at an advisory board for Gilead and Novigenix. He has received speaking fees from Vifor, MSD and Takeda and traveling fees from Vifor, Novartis, MSD, Gilead and Takeda. B.M. has received a research grant from MSD unrelated to this work. C.P. has participated in advisory boards for Biogen, Celgene, Merck, Novartis and Roche none related to this work. A.W. is currently an employee of Abbvie. G.R. has consulted to Abbvie, Augurix, BMS, Boehringer, Calypso, Celgene, FALK, Ferring, Fisher, Genentech, Gilead, Janssen, MSD, Novartis, Pfizer, Phadia, Roche, UCB, Takeda, Tillots, Vifor, Vital Solutions and Zeller; GR has received speaker's honoraria from Astra Zeneca, Abbvie, FALK, Janssen, MSD, Pfizer, Phadia, Takeda, Tillots, UCB, Vifor and Zeller; G.R. has received educational grants and research grants from Abbvie, Ardeypharm, Augurix, Calypso, FALK, Flamentera, MSD, Novartis, Pfizer, Roche, Takeda, Tillots, UCB, and Zeller. L.B. reports fees for consulting/advisory board from Abbvie, MSD, Vifor, Falk, Esocap, Calypso, Ferring, Pfizer, Shire, Takeda, Janssen, Ewopharma. M.C.S. has received consultant and/or speaker fees from Abbvie, Ferring, MSD, Janssen, Pfizer, Takeda, and UCB. P.J. has received a research grant from Vifor unrelated to this work. S.B. received fees for consulting and advisory boards and speaker's honoraria from AbbVie, Falk, Janssen‐Cilag AG, MSD, Pfizer, Takeda, UCB Pharma and Vifor Pharma. R.R. has served at an advisory board for Lilly and has received travel fees from AbbVie AG. T.G. has consulting contracts with Sanofi‐Regeneron and Falk Pharma GmbH, received travel grants from Falk Pharma GmbH and Vifor, and an unrestricted research grant from Novartis. E.B. received consultant and/or speaker fees from Abbvie, Janssen, MSD, Norgine, Pfizer, Takeda, and Sandoz. J.C.M. has served at advisory boards and received honoraria from Abbvie, Bayer, BMS, Eisai, Gilead, Incyte, Intercept, Ipsen, MSD, Roche, Sanofi, SigmaTau. J.C.M. received grants from Abbvie, Gilead, and Falk. Funding Information: The authors would like to thank Andreas Sailer, Novartis Institute of Biomedical Research, Basel, Switzerland, for generously providing an GPR183(EBI2)-antibody and stimulating discussions. This work was supported by grants from the Swiss National Science Foundation (SNF) to B.M. (grant no. 32473B_156525), to C.P. (grant no. PP00P3_157476) and to G.R. (for the Swiss IBD Cohort, grant no. 33CS30_148422), a grant from the Leenaards Foundation to C.P. and a grant from the Hartmann-Müller Foundation to B.M. F.R. holds a MD-PhD grant from the SNF (#323630-183987).

PY - 2021/8

Y1 - 2021/8

KW - FACS

KW - GPR183/EBI2

KW - IBD

KW - SNP

KW - UBAC2

KW - psoriasis

UR - http://www.scopus.com/inward/record.url?scp=85102453628&partnerID=8YFLogxK

U2 - 10.1111/bph.15395

DO - 10.1111/bph.15395

M3 - Article

C2 - 33511653

AN - SCOPUS:85102453628

SN - 0007-1188

VL - 178

SP - 3157

EP - 3175

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

IS - 16

ER -